Stimulates cell regeneration and repair, improving skin texture and resilience
The optimal dosage range for most users falls between 20-50 mcg per day administered via subcutaneous or intramuscular injection
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
The straightforward answer: continuing your GLP-1 injection schedule during your period is medically sound, though some patients report cycle-related changes in appetite or nausea that may influence how they experience their medication
doi:10.1177/2042018810380215 [3] Hu D, Xie F, Xiao Y, et al
Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice
